论文部分内容阅读
目的:观察重组组织型纤溶酶原激活物(rt-PA)治疗急性缺血性卒中(CIS)合并大脑中动脉高密度征(HMCAS)的临床疗效。方法:107例CIS合并HMCAS的住院患者随机分为对照组(54例)和观察组(53例)。对照组予尿激酶治疗,观察组予rtPA治疗,疗程均为14 d。治疗结束后评价两组患者的临床疗效与安全性。结果:与治疗前比较,两组患者各阶段NIHSS评分均明显降低,BI指数则明显升高(P<0.05);且观察组两项指标均优于对照组(P<0.05)。观察组有效率为88.68%,高于对照组的79.63%(P<0.05)。结论:rt-PA静脉溶栓治疗CIS合并HMCAS患者疗效显著,并能改善患者生活质量,值得推广。
Objective: To observe the clinical efficacy of recombinant tissue plasminogen activator (rt-PA) in the treatment of acute ischemic stroke (CIS) combined with high-density middle cerebral artery disease (HMCAS). Methods: A total of 107 inpatients with CIS and HMCAS were randomly divided into control group (54 cases) and observation group (53 cases). The control group was treated with urokinase and the observation group was treated with rtPA for 14 days. After treatment, the clinical efficacy and safety of the two groups were evaluated. Results: Compared with those before treatment, the NIHSS scores of the two groups were significantly decreased and the BI index was significantly increased (P <0.05). The two indexes in the observation group were better than those in the control group (P <0.05). The effective rate of the observation group was 88.68%, which was higher than that of the control group (79.63%, P <0.05). Conclusion: rt-PA intravenous thrombolysis in patients with CIS combined with HMCAS significant effect, and can improve the quality of life of patients, it is worth promoting.